| Authors: |
Langevin N; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 06877, United States., Shukla A; IQVIA, Bengaluru 560103, India., Bogoeva N; Putnam Associates, London WC1E 7HJ, United Kingdom., Kéri P; GAMIAN-Europe, 1000 Brussels, Belgium., Kostikas M; IQVIA, 1101 CT Amsterdam, Netherlands., Sgarbi S; IQVIA, 28007 Madrid, Spain., Lawhorn W; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 06877, United States., Pott V; Boehringer Ingelheim International GmbH, 55218 Ingelheim am Rhein, Germany., Fowler JC; Boehringer Ingelheim International GmbH, 55218 Ingelheim am Rhein, Germany., Sommer S; Boehringer Ingelheim International GmbH, 55218 Ingelheim am Rhein, Germany., Wang J; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 06877, United States., Nagendra A; Schizophrenia and Psychosis Action Alliance, Alexandria, VA 22301, United States., Medalia A; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY 10032, United States., Reaney M; IQVIA, Reading RG1 3JH, United Kingdom. |